ArticleFrontiers in immunology2026
Berberine restrains the expansion of colorectal cancer organoids by blocking cell cycle progression and reducing lipid synthesis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Among all the most prevalent malignant gastrointestinal cancers, colorectal cancer (CRC) occurs frequently in all the populations around the world. Despite remarkable advances in related research, substantial obstacles persist in the prevention and treatment of this malignancy, including safety concerns, adverse side effects, and tumor recurrence. Natural plant-derived compounds have increasingly attracted the attention of researchers in cancer research. Among these compounds, berberine (BBR) is a natural plant substance with multiple functions, which is extracted from Methods: We firstly established CRC organoid models derived from KPC transgenic mice and Caco-2 cell line. CRC organoids were treated with different doses of BBR. The morphological characteristics, proliferation, ROS, apoptosis, and cell cycle were carefully evaluated. RNA-Seq assay, epithelial permeability, and lipid probes were also used to examine the underlying molecular mechanisms of BBR on CRC organoids. Results: BBR exhibited no harmful impact on healthy colonic tissues. However, BBR significantly inhibited the growth of both KPC organoids and Caco-2 organoids either at the early formation stage or after the maturity. BBR greatly decreased the ratio of Ki67 and EdU positive cells in CRC organoids and increased the level of ROS in organoids. RNA-Seq data implicated that BBR exerted direct cytotoxic effects on CRC organoids by inducing cell cycle arrest and breaking down the gap junctions. Immunohistochemical (IHC) staining identified the consistent changes of cell cycle arrest and dysfunction of epithelial barrier. FD4 staining showed increased epithelial permeability. Finally, LD540 probes and qPCR identified that BBR significantly blocked the lipid synthesis in CRC organoids. Conclusions: In summary, our study identifies that BBR may suppress the malignant phenotype of CRC organoids via multiple mechanisms, including blocking cell cycle progression and disrupting lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.